Jeffrey Ulmer
President C-Suite TechImmune
Jeffrey B. Ulmer, Ph.D. spent more than 30 years in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis and GlaxoSmithKline. His most recent leadership positions included Global Head, External R&D; Head, Preclinical R&D; and Program Head, Technical R&D. His scientific focus has been vaccine technology platforms, including DNA and mRNA vaccines, viral vectors and adjuvants. He received a Ph.D. in biochemistry from McGill University and a postdoctoral fellowship in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. He has published over 220 scientific articles, is an inventor on 11 patents, and is a Fellow of the International Society for Vaccines, where he serves as Treasurer. He is currently President of TechImmune Inc, a biotechnology company based in Newport Beach, CA.
Seminars
- Persistent virus reservoirs associated with dysfunctional anti-viral T cell responses is a root cause of Long COVID, a debilitating disease affecting >400 million people globally
- We have developed an mRNA-based immunotherapeutic targeting protective T cell antigens of SARS-CoV-2
- Treatment of Long COVID in mice resulted in reversal of T cell dysfunction, clearance of virus reservoirs, and amelioration of cognitive and behavioural deficits
Key questions include:
- How do you structure CDMO partnerships to balance speed, flexibility, and risk without overcomplicating your manufacturing network?
- What are the biggest misalignments between biopharma and CDMOs during scale-up – and how can they be avoided early?
- At what point should companies start designing for commercial-scale manufacturing, and how does that shape CDMO and supply chain decisions?
